CHOICE AND COMBINATION OF ANTIPLATELET MEDICATIONS IN ST ELEVATION MYOCARDIAL INFARCTION
https://doi.org/10.17802/2306-1278-2013-3-62-71
Abstract
The state of the art in antiplatelet therapy in ST elevation myocardial infarction patients was reviewed. The possibility of clopidogrel substitution for the newer and more potent antiplatelet drugs such as ticagrelor and prasugrel was discussed. The rationale for the use of each medication was presented. The results of clinical trials comparing clopidogrel with ticagrelor and prasugrel were analyzed. It was highlighted that only ticagrelor can substitute clopidogrel and only in primary coronary intervention setting. In other settings including thrombolytic therapy, pharmacoinvasive approach or no reperfusion, clopidogrel has no alternatives as a part of dual antiplatelet therapy in ST elevation myocardial infarction. It was observed that with dual antiplatelet therapy the rationale for GPIIb/IIIa inhibitors use during percutaneous coronary interventions became significantly different in the category of patients under discussion.
About the Author
O. V. Averkov
City Clinical Hospital № 15 n. a. O. M. Filatov and People’s Friendship University of Russia, Moscow
Russian Federation
Russian Federation
References
1. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines / Kushner F. G. [et al.] // J. Am. Coll. Cardiol. 2009. Vol. 54. P. 2205–2241.
2. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines / O’Gara P. T. [et al.] // Circulation. 2013. Vol. 127, № 4. Р. 529–555.
3. Acute Myocardial Infarction in patients presenting with ST-segment elevation (Management of) / Steg G. [et al.] // European Heart Journal. 2012. Vol. 33. Р. 2569–2619.
4. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation / Sabatine M. S. [et al.] // N. Engl. J. Med. 2005. Vol. 352. P. 1179–1189.
5. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomized placebo-controlled trial / COMMIT collaborative group // Lancet. 2005. Vol. 366. P. 1607–1621.
6. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial / James S/ [ et al.] // Am. Heart J. 2009. Vol. 157. P. 599–605.
7. Double-dose versus standard-dose clopidogrel and highdose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial / Mehta S. R. [et al.] // Lancet. 2010. Vol. 76. P. 1233–1243.
8. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study / Sabatine M. S. [et al.] // J. Am. Med. Assoc. 2005. Vol. 294. P. 1224–1232.
9. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology / Van De Werf F. [et al.] // Eur. Heart J. 2008. Vol. 29. P. 2909–2945.
10. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomized controlled trial / Montalescot G. [et al.] // Lancet. 2009. Vol. 373. P. 723–731.
11. Prasugrel versus clopidogrel in patients with acute coronary syndromes / Wiviott S. D. [et al.] // N. Engl. J. Med. 2007. Vol. 357. P. 2001–2015.
Review
For citations:
Averkov O.V. CHOICE AND COMBINATION OF ANTIPLATELET MEDICATIONS IN ST ELEVATION MYOCARDIAL INFARCTION. Complex Issues of Cardiovascular Diseases. 2013;(3):62-71. (In Russ.) https://doi.org/10.17802/2306-1278-2013-3-62-71
Views:
715
